TY  - JOUR
AU  - Paré, L
AU  - Pascual, T
AU  - Seguí, E
AU  - Teixidó, C
AU  - Gonzalez-Cao, M
AU  - Galván, P
AU  - Rodríguez, A
AU  - González, B
AU  - Cuatrecasas, M
AU  - Pineda, E
AU  - Torné, A
AU  - Crespo, G
AU  - Martin-Algarra, S
AU  - Pérez-Ruiz, E
AU  - Reig, Ò
AU  - Viladot, M
AU  - Font, C
AU  - Adamo, B
AU  - Vidal, M
AU  - Gaba, L
AU  - Muñoz, M
AU  - Victoria, I
AU  - Ruiz, G
AU  - Viñolas, N
AU  - Mellado, B
AU  - Maurel, J
AU  - Garcia-Corbacho, J
AU  - Molina-Vila, M Á
AU  - Juan, M
AU  - Llovet, J M
AU  - Reguart, N
AU  - Arance, A
AU  - Prat, A
PY  - 2018
DO  - 10.1093/annonc/mdy335
UR  - https://hdl.handle.net/10668/26687
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - We hypothesized that the abundance of PD1 mRNA in tumor samples might explain the differences in overall response rates (ORR) observed following anti-PD1 monotherapy across cancer types. RNASeqv2 data from 10 078 tumor samples representing 34...
LA  - en
KW  - Antineoplastic Agents, Immunological
KW  - Biomarkers, Tumor
KW  - CD8-Positive T-Lymphocytes
KW  - Cohort Studies
KW  - Female
KW  - Follow-Up Studies
KW  - Gene Expression Regulation, Neoplastic
KW  - Humans
KW  - Lymphocytes, Tumor-Infiltrating
KW  - Male
KW  - Middle Aged
KW  - Neoplasms
KW  - Prognosis
KW  - Programmed Cell Death 1 Receptor
KW  - RNA, Messenger
KW  - Survival Rate
TI  - Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.
TY  - research article
VL  - 29
ER  -